Advancing the registrational open-label pivotal study of LX2006 in Friedreich ataxia (FA) cardiomyopathy. The study will evaluate high-dose LX2006 in 13 treated participants compared to 13 untreated controls, using left ventricular mass index (LVMI) as the primary endpoint.

Expected impact: Establish clinical proof-of-concept and provide the primary clinical evidence required to support accelerated FDA approval of LX2006.

Transitioning the manufacturing process of LX2006 from a HEK293-based platform to an optimized, high-yield Sf9-baculovirus AAV manufacturing platform.

Expected impact: Improves scalability, reduces cost of goods, and supports commercial-scale production readiness for BLA submission.

Conducting a prospective natural history study of patients with Friedreich ataxia cardiomyopathy to provide supportive evidence on the untreated disease course.

Expected impact: Provides critical comparative data on the untreated disease course to support both accelerated and full regulatory approval pathways.